A Real-World Comparison of Apixaban and Rivaroxaban in Obese and Morbidly Obese Patients With Nonvalvular Atrial Fibrillation.

Contemporary guidelines for managing nonvalvular atrial fibrillation (NVAF) include apixaban and rivaroxaban as first-line anticoagulation treatment options. Minimal guidance is available regarding selecting anticoagulants for patients with class I-III obesity. This study aims to evaluate the comparative effectiveness and safety of apixaban and rivaroxaban in both obese and morbidly obese patients with NVAF.

Methods and Barriers to Communication Between Pharmacists During Transitions of Care.

Effective communication between pharmacists across healthcare settings is essential to facilitate transitions of care (TOC) and improve patient outcomes. To explore pharmacists' communication methods and preferences and identify barriers to communication during TOC. A survey was distributed to a convenience sample of pharmacists in California, Connecticut, Illinois, Massachusetts, New Jersey, and Texas.

The Effects of Participation in a Transitions of Care Simulation on Pharmacy Students' Empathy.

To assess the effects of a transitions of care simulation on the empathy of pharmacy students. Pharmacy students volunteered to complete a four-hour transitions of care simulation. Students were "discharged" from a simulation hospital by trained actors posing as health care providers and provided with a discharge packet, prescriptions, bus route, and bus pass.

Psychiatric Manifestations With Sacubitril/Valsartan: A Case Report.

Sacubitril/valsartan is an angiotensin receptor-neprilysin inhibitor approved for the treatment of heart failure with reduced ejection fraction (HFrEF). Valsartan is well studied, but sacubitril has much left to understand. This report describes a 31-year-old African American female diagnosed with HFrEF who presented with a 7-day history of psychiatric symptoms following a dose increase in sacubitril/valsartan.